Clinical Trials Directory

Trials / Completed

CompletedNCT00018668

Antipsychotic Response in Schizophrenia

Psychopharmacologic Aspects of Motor Slowing in Schizophrenia

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
Sponsor
US Department of Veterans Affairs · Federal
Sex
All
Age
21 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Motor slowing is a hallmark, clinical sign in mental illness. Slowness can be related to a specific disease process, as in negative schizophrenia or depression or it can be the result of medications used to treat forms of mental illness. Prior research has lead to a novel instrumental approach for distinguishing subtypes of motor slowing - one type related to cognitive processes and another related to parkinsonism. The purpose of this study is to test whether new medications used to treat schizophrenia improve the cognitive or parkinsonian components of motor slowing. Patients will be studied in the laboratory before and 8-weeks after starting a new antipsychotic. The n of this study = 60 patients. The results of this study will improve our understanding of the complex interactions between cognitive processing and motor behavior in patients with psychotic illnesses and how drugs work to treat these problems.

Conditions

Interventions

TypeNameDescription
DRUGRisperidone
DRUGOlanzapine
DRUGQuetiapine

Timeline

Start date
2000-10-01
Completion
2004-09-01
First posted
2001-07-05
Last updated
2009-01-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00018668. Inclusion in this directory is not an endorsement.